Non-improvement predicts subsequent non-response to repeated-dose intravenous ketamine for depression: a re-analysis of a 2-week open-label study in patients with unipolar and bipolar depression-Reference-Cited by-同舟云学术

Non-improvement predicts subsequent non-response to repeated-dose intravenous ketamine for depression: a re-analysis of a 2-week open-label study in patients with unipolar and bipolar depression

Published:2024-08-06 Issue:1 Volume:14 Page:
ISSN:2158-3188
Container-title:Translational Psychiatry
language:en
Short-container-title:Transl Psychiatry

Author:

Wang Chengyu^ORCID,Lan Xiaofeng,Liu Weijian,Zhan Yanni,Zheng Wei^ORCID,Chen Xiaoyu^ORCID,Liu Guanxi,Mai Siming,Lu Hanna^ORCID,McIntyre Roger S.,Zhou Yanling^ORCID,Ning Yuping^ORCID

Publisher

Springer Science and Business Media LLC

Link

https://www.nature.com/articles/s41398-024-03027-2.pdf

Reference53 articles.

1. Marcantoni WS, Akoumba BS, Wassef M, Mayrand J, Lai H, Richard-Devantoy S, et al. A systematic review and meta-analysis of the efficacy of intravenous ketamine infusion for treatment resistant depression: January 2009 – January 2019. J Affect Disord. 2020;277:831–41.

2. Wilkinson ST, Ballard ED, Bloch MH, Mathew SJ, Murrough JW, Feder A, et al. The effect of a single dose of intravenous ketamine on suicidal ideation: a systematic review and individual participant data meta-analysis. Am J Psychiatry. 2018;175:150–8.

3. Salloum NC, Fava M, Hock RS, Freeman MP, Flynn M, Hoeppner B, et al. Time to relapse after a single administration of intravenous ketamine augmentation in unipolar treatment-resistant depression. J Affect Disord. 2020;260:131–9.

4. Mathew SJ, Murrough JW, aan het Rot M, Collins KA, Reich DL, Charney DS. Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: a pilot randomized, placebo-controlled continuation trial. Int J Neuropsychopharmacol. 2010;13:71–82.

5. Costi S, Soleimani L, Glasgow A, Brallier J, Spivack J, Schwartz J, et al. Lithium continuation therapy following ketamine in patients with treatment resistant unipolar depression: a randomized controlled trial. Neuropsychopharmacol. 2019;44:1812–9.